linjc16/ctgov huggingface dataset:
A Clinical Study of Iobitridol in Patients Undergoing Multislice Computed Tomography (CT) Abdominal Angiography

Study Overview
=================
Brief Summary
-----------------
This is a clinical study of iobitridol in patients undergoing multislice CT (MSCT) abdominal angiography.

Official Title
-----------------
A Clinical Study of Iobitridol in Multislice CT Abdominal Angiography Indications

Conditions
-----------------
Diagnostic Imaging

Intervention / Treatment
-----------------
* Drug: Iobitridol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female having reached legal majority age and up to 85 years included. Scheduled for an aorta and abdominal arterial tree evaluation by MSCT, either for pre-therapeutic evaluation or for post-surgical control or follow-up (including patients with prosthetic vascular material). Female of childbearing potential must have effective contraception (contraceptive pill or intra-uterine device), or be surgically sterilised, or post-menopausal (minimum 12 months amenorrhea) or must have a documented negative urine and/or blood pregnancy test at screening. Exclusion Criteria: Patients with overt non-compensated heart failure. Patients with hemodynamic instability. Patients with ESC (European Society of Cardiology)/ESH (European Society of Hypertension) grade 3 hypertension (SBP [systolic blood pressure) over or equal to 180 mm Hg or DBP [diastolic blood pressure] over or equal to 110 mm Hg) Patients with known severe renal failure (defined as creatinine clearance < 30 ml/min as calculated by the Cockroft and Gault formula). Patients who have received diuretic or biguanide treatment during the 48 hours preceding the MSCT scan. Patients with known thyreotoxicosis. Patients with history of immediate or delayed major hypersensitivity reaction to iodinated contrast media.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Iobitridol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MSCT indications
Research on Accurate Prediction of Long-term Medication Use for Schizophrenia Based on Cognitive Function

Study Overview
=================
Brief Summary
-----------------
Chinese version of the cognitive function test of schizophrenia (MCCB) . To explore a predictive model for long-term medication use in patients based on cognitive function

Official Title
-----------------
Research on Accurate Prediction of Long-term Medication Use for Schizophrenia Based on Cognitive Function

Conditions
-----------------
Non-medicine Intervention

Intervention / Treatment
-----------------
* Drug: non-medicine intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Schizophrenia patients with first episode and disease duration of 5, 10, 20, and 30 years _Meet the diagnostic criteria for schizophrenia in ICD-10 Exclusion Criteria: Other people with mental illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| schizophrenia patient group<br>Schizophrenia patients with first episode and disease duration of 5, 10, 20, and 30 years | Drug: non-medicine intervention<br>* rating by MCCB only one time<br>* Other names: rating by MATRICS Consensus Cognitive Battery,MCCB;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score of MATRICS Consensus Cognitive Battery |  | 1 day (only one time) |
Comparison of 30% Metformin and 2% Nicotinamide Lotion With Kligman Formula in the Treatment of Melasma

Study Overview
=================
Brief Summary
-----------------
Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma

Detailed Description
-----------------
A comparative study to evaluate Efficacy and tolerability of new lotion in the treatment of Melasma.

Official Title
-----------------
Comparison of 30% Metformin and 2% Nicotinamide Lotion With Kligman Formula in the Treatment of Melasma

Conditions
-----------------
Melasma

Intervention / Treatment
-----------------
* Drug: Metformin and Nicotinamide vs Kligman Formula


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18-50 No systemic therapy All Co-morbids Exclusion Criteria: Pregnancy Age >50 Taking oral treatment for melasma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Metformin 30% and 2% Nicotinamispde<br>Metformin 30% plus Nicotinamide 2% in the reatment of Melasma | Drug: Metformin and Nicotinamide vs Kligman Formula<br>* Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma<br>|
| Active Comparator: Kligman formula<br>Kligman formula in the treatment of Melasma | Drug: Metformin and Nicotinamide vs Kligman Formula<br>* Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma | Efficacy with measurement of MASI score 4 weeks apart | 12 weeks |
Immune Response Features in Allergic Airway Diseases

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate immune mechanisms and phenotypes and endotypes of allergic airway diseases - allergic rhinitis and allergic asthma. Pathogenesis of these diseases are not fully investigated yet. Patients with the same disease have different dominant symptoms, course of the disease and response to treatment. Moreover, there is a hypothesis about united airway disease suggesting that allergic rhinitis and allergic asthma is different manifestation of the same disease. This led to assumption of phenotypes and endotypes. This classification which still is not unified can let to prescribe personalized treatment for every patient.

Official Title
-----------------
Investigation of Phenotypes, Endotypes and Immune Response Features in Allergic Airway Diseases

Conditions
-----------------
Allergic Asthma, Allergic Rhinitis

Intervention / Treatment
-----------------
* Procedure: Nasal provocation test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hypersensitivity to house dust mites Allergic rhinitis with or without mild to moderate asthma Exclusion Criteria: Acute or chronic infections Use of systemic immunosupresants (wait 1 month) Use of systemic or local antihistamines (wait 1 week) Use of intranasal steroids (wait 1 month) Oncological or active autoimmune diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Allergic rhinitis patients<br> | Procedure: Nasal provocation test<br>* Allergen extract under controlled conditions will be applied into nasal mucous.<br>|
| Allergic rhinitis and asthma patients<br> | Procedure: Nasal provocation test<br>* Allergen extract under controlled conditions will be applied into nasal mucous.<br>|
| Healthy individuals<br> | Procedure: Nasal provocation test<br>* Allergen extract under controlled conditions will be applied into nasal mucous.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cytokines level in nasal lavage and peripheral blood after nasal provocation test in different groups. | Cytokines (IL-13, IL-10, IL-22, etc.) level will be measured by ELISA before and after nasal provocation test with house dust mites. Comparison between different groups. | 2 hours | 
| Cytokines level in nasal lavage and peripheral blood after nasal provocation test in different groups. | Cytokines (IL-13, IL-10, IL-22, etc.) level will be measured by ELISA before and after nasal provocation test with house dust mites. | 22 hours |
Internal Hernia After Laparoscopic Gastric Bypass

Study Overview
=================
Brief Summary
-----------------
To see if closing the mesenteric defects created at a Laparoscopic Gastric Bypass is better than leaving them open.

Detailed Description
-----------------
When the patients who has undergone a Laparoscopic Gastric Bypass lose weight, the mesenteric defects that are inevitable to cause, gets bigger and can cause an internal hernia (IH). This study will observe whether it is better to close the defects or leave them open. The patients will be randomized into two groups. One, where the defects are closed with sutures and one where the defects are left alone. The primary endpoint of the study is the prevalence of surgery for obstruction. Information about this will be gathered through the national register for obesity surgery in Sweden, SOReg. Each arm in the study will include 1200 patients and the follow up period will be three years. Since the register mentioned above is an ongoing register, the results can be studied over a longer period if wanted. The national hospital registry will further improve the follow-up.

Official Title
-----------------
Internal Hernia After Laparoscopic Gastric Bypass

Conditions
-----------------
The Prevalence of Surgery for Small Bowel Obstruction After LGBP Procedure.

Intervention / Treatment
-----------------
* Procedure: Suturing of mesenteric defects


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient accepted for a Laparoscopic Gastric Bypass that has given a written consent Exclusion Criteria: Conversion to open surgery prior to the randomization Patients not giving a written consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mesenteric defects sutured<br>Closure of the mesenteric defects using running, non-absorbable suture | Procedure: Suturing of mesenteric defects<br> <br> |
| No Intervention: Mesenteric defects not sutured<br>Non-closure of the mesenteric defects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgery for small bowel obstruction after a LGBP procedure. |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serious Complications | Defined as Clavien grade 3b or more | within 2 years after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Small bowel obstruction, Laparoscopic gastric bypass, Internal Hernia, Mesenteric defect, Morbid obesity
How Useful is the Advice: Fill up a Handful of Sunscreen and Spread it All Over Your Body

Study Overview
=================
Brief Summary
-----------------
The advice: Fill up a handful of sunscreen and spread it all over your body is used in several sun safety campaigns. The hope is that users in swimwear following the advice will apply a sunscreen quantity of 2 mg/cm^2 to all accessible skin. The present study is the first to investigate how this advice works in practice.

Official Title
-----------------
How Useful is the Advice: Fill up a Handful of Sunscreen and Spread it All Over Your Body

Conditions
-----------------
Quantity of Sunscreen, Sun Protection Factor, Sun Safety Campaigns, Sunscreen Use

Intervention / Treatment
-----------------
* Behavioral: Fill up a handful of sunscreen and spread it all over your body. Sunscreen, Actinica


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - European descent Exclusion Criteria: Skin disease allergy to the content in sunscreen Pregnancy Breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Fill up a handful of sunscreen and spread it all over your body. Sunscreen, Actinica|Volunteers were asked to follow the rule of thumb: Fill up a handful of sunscreen and spread it all over your body.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The overall quantities of sunscreen applied were calculated from the weighed amount of sunscreen used divided by the skin area accessible for sunscreen application. |  | Outcome measure will be assessed within half an hour after sunscreen application. There will be no further follow up. |
Alpha-1 Foundation Research Registry

Study Overview
=================
Brief Summary
-----------------
The Alpha-1 Foundation Research Registry is a confidential database made up of individuals diagnosed with severe alpha-1 antitrypsin deficiency (Alpha-1) or the carrier state.

Detailed Description
-----------------
The Registry was established in 1997 by the Alpha-1 Foundation to facilitate research initiatives and promote the development of improved treatments and a cure for Alpha-1. Located at the Medical University of South Carolina (MUSC) in Charleston, the Registry employs procedures that ensure the most stringent confidentiality of participants. The Registry operates under the direction of the Alpha-1 Foundation Board of Directors and is guided by an Advisory Committee comprised of leaders in the medical, ethical, scientific and Alpha communities. Individuals enrolled in the Registry have the ongoing opportunity to participate directly in clinical trials of new therapeutic approaches in addition to other research opportunities.

Official Title
-----------------
Alpha-1 Foundation Research Registry

Conditions
-----------------
Alpha 1-Antitrypsin Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals of all ages who are diagnosed with severe alpha-1 antitrypsin deficiency or the carrier state
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To study the natural history of PiZZ, PiSZ, and PiMZ alpha-1 antitrypsin deficiency |  | Not limited | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alpha 1-Antitrypsin Deficiency
Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.

Study Overview
=================
Brief Summary
-----------------
To determine, in subjects with Type 1 Diabetes Mellitus: Whether glycemic control can be achieved at least as effectively with an insulin regimen involving pre-meal inhaled insulin plus a single bedtime Ultralente injection as with a conventional subcutaneous insulin regimen involving 2-3 mixed Regular/NPH insulin injections per day. The toleration and safety of inhaled insulin therapy and its effects after 6 months, if any, on measures of pulmonary function.

Official Title
-----------------
Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin Therapy in Subjects With Type 1 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial

Conditions
-----------------
Diabetes Mellitus, Type 1

Intervention / Treatment
-----------------
* Drug: Inhaled human insulin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 1 Diabetes for more than 1 year Stable insulin regimen of at least 2 injections per day Exclusion Criteria: Any smoking within the last 6 months. Smoking is not permitted at any time during this study. Subjects on insulin pump during 2 months prior to screening. Subjects with poorly-controlled asthma, clinically significant chronic obstructive pulmonary disease, or other significant respiratory disease.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Inhaled human insulin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary outcome is 24 week change in baseline in HbA1c |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary endpoints include the following efficacy assessments: |  |  | 
| Incidence of hypoglycemia |  |  | 
| Proportion of subjects with acceptable glycemic control (e.g., HbA1c<8%) |  |  | 
| Change from baseline in fasting lipid profile |  |  | 
| Change from baseline in fasting plasma glucose level |  |  | 
| Change from baseline in meal glucose response (2-hour postprandial increment in plasma glucose) |  |  | 
| Dose of insulin (total dose of injected sustained-duration insulin, and total dose of inhaled or injected Regular insulin during the study). |  |  | 
| Change from baseline in body weight |  |  | 
| Change from baseline in 24-hour home glucose profile (based on the area under the glucose profile curve calculated by the trapezoid rule with special weights assigned to the pre-breakfast and bedtime assessments). |  |  | 
| Patient satisfaction and preference. |  |  |
An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety and tolerability of topical C-KAD Ophthalmic Solution in reducing intraocular pressure in patients with ocular hypertension.

Official Title
-----------------
A Pilot, Open-Label, Controlled Clinical Trial of C-KAD Ophthalmic Solution in Reducing Intraocular Pressure in Patients With Ocular Hypertension

Conditions
-----------------
Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: C-KAD Ophthalmic Solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both eyes having intraocular pressure in the range of 22-30 mmHg at baseline Both eyes having best corrected visual acuity better than 20/50 Exclusion Criteria: Advanced glaucoma Closed or barely open anterior chamber or history of angle closure

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: C-KAD Ophthalmic Solution<br> | Drug: C-KAD Ophthalmic Solution<br>* 4 drops applied daily for 150 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change in intraocular pressure from baseline |  | 150 Days |